Company intelligence / Profile preview

Sarcio

St. Louis, Missouri, United States

Ownership: Private
Development stage: Other

Overview

Sarcio is a regenerative medicine company focused on developing cell-based therapies for the treatment of osteoarthritis and other cartilage-related disorders. The company utilizes a proprietary platform to differentiate induced pluripotent stem cells (iPSCs) into high-quality chondrocytes, the cells responsible for maintaining cartilage. By providing a scalable source of healthy cartilage cells, Sarcio aims to offer a disease-modifying treatment that can repair joint damage and reduce pain. The company's lead programs are currently in the pre-clinical stage, targeting significant unmet needs in orthopedic health.

Therapeutic areas: Rheumatology
Modalities: Induced pluripotent stem cell derived therapyCell therapyBiologic
Industry: Biotech

Partnerships

Washington University in St. Louis

Beyond the preview

Go deeper on Sarcio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sarcio.

Explore the full profile